Price Target Changed • Jun 18
Price target increased by 10% to €698 Up from €632, the current price target is an average from 2 analysts. New target price is 40% above last closing price of €498. Stock is up 28% over the past year. The company is forecast to post earnings per share of €35.60 for next year compared to €19.11 last year. Reported Earnings • May 14
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: €19.11 (up from €10.61 in FY 2024). Revenue: €53.9m (up 44% from FY 2024). Net income: €5.69m (up 83% from FY 2024). Profit margin: 11% (up from 8.3% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 5.8%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 14% per year. Announcement • May 12
LIMES Schlosskliniken AG, Annual General Meeting, Jun 19, 2026 LIMES Schlosskliniken AG, Annual General Meeting, Jun 19, 2026, at 14:00 W. Europe Standard Time. Announcement • Apr 29
LIMES Schlosskliniken AG announces Annual dividend, payable on June 24, 2026 LIMES Schlosskliniken AG announced Annual dividend of EUR 10.0000 per share payable on June 24, 2026, ex-date on June 22, 2026 and record date on June 23, 2026. New Risk • Mar 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Price Target Changed • Feb 07
Price target increased by 12% to €710 Up from €632, the current price target is provided by 1 analyst. New target price is 52% above last closing price of €466. Stock is up 33% over the past year. The company is forecast to post earnings per share of €23.78 for next year compared to €10.61 last year. New Risk • Jan 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €426, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 16x in the Healthcare industry in Germany. Total returns to shareholders of 35% over the past three years. Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €378, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 15x in the Healthcare industry in Germany. Total returns to shareholders of 20% over the past three years. Valuation Update With 7 Day Price Move • Sep 01
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €400, the stock trades at a trailing P/E ratio of 38.6x. Average trailing P/E is 20x in the Healthcare industry in Germany. Total returns to shareholders of 52% over the past three years. Reported Earnings • May 15
Full year 2024 earnings released: EPS: €10.61 (vs €11.59 in FY 2023) Full year 2024 results: EPS: €10.61 (down from €11.59 in FY 2023). Revenue: €38.1m (up 2.6% from FY 2023). Net income: €3.11m (down 8.4% from FY 2023). Profit margin: 8.2% (down from 9.1% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Announcement • Apr 30
LIMES Schlosskliniken AG, Annual General Meeting, Jun 06, 2025 LIMES Schlosskliniken AG, Annual General Meeting, Jun 06, 2025, at 14:00 W. Europe Standard Time. Valuation Update With 7 Day Price Move • Apr 25
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to €314, the stock trades at a trailing P/E ratio of 21.5x. Average forward P/E is 13x in the Healthcare industry in Germany. Total returns to shareholders of 21% over the past three years. New Risk • Mar 23
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€84.4m market cap, or US$91.4m). New Risk • Feb 19
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €92.6m (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risk Market cap is less than US$100m (€92.6m market cap, or US$96.4m). New Risk • Dec 16
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €90.9m (US$95.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risk Market cap is less than US$100m (€90.9m market cap, or US$95.6m). Announcement • Jul 18
LIMES Schlosskliniken AG to Report First Half, 2024 Results on Sep 03, 2024 LIMES Schlosskliniken AG announced that they will report first half, 2024 results on Sep 03, 2024 Reported Earnings • May 19
Full year 2023 earnings released: EPS: €11.58 (vs €14.34 in FY 2022) Full year 2023 results: EPS: €11.58 (down from €14.34 in FY 2022). Revenue: €38.0m (up 32% from FY 2022). Net income: €3.40m (down 19% from FY 2022). Profit margin: 8.9% (down from 15% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year whereas the company’s share price has increased by 39% per year. New Risk • Mar 22
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (36% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€86.2m market cap, or US$93.2m). New Risk • Oct 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (36% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (€72.7m market cap, or US$76.9m). Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €248, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 18x in the Healthcare industry in Germany. Total returns to shareholders of 146% over the past three years. Valuation Update With 7 Day Price Move • Sep 22
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €274, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 21x in the Healthcare industry in Germany. Total returns to shareholders of 211% over the past three years. Announcement • Jun 23
LIMES Schlosskliniken AG (XTRA:LIK) acquired additional 5% stake in PRC Group AG. LIMES Schlosskliniken AG (XTRA:LIK) acquired additional 5% stake in PRC Group AG on June 22, 2023. The remaining 44 percent are held by the management of the Paracelsus Group. The financing of the transaction follows from liquid funds of the LIMES Group.
LIMES Schlosskliniken AG (XTRA:LIK) completed the acquisition of additional 5% stake in PRC Group AG on June 22, 2023. Reported Earnings • Sep 18
First half 2022 earnings released: EPS: €6.52 (vs €5.29 in 1H 2021) First half 2022 results: EPS: €6.52 (up from €5.29 in 1H 2021). Revenue: €13.3m (up 63% from 1H 2021). Net income: €1.91m (up 23% from 1H 2021). Profit margin: 14% (down from 19% in 1H 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 14
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €224, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 16x in the Healthcare industry in Germany. Total returns to shareholders of 127% over the past three years. Reported Earnings • May 21
Full year 2021 earnings released: EPS: €13.45 (vs €2.37 loss in FY 2020) Full year 2021 results: EPS: €13.45 (up from €2.37 loss in FY 2020). Revenue: €23.4m (up 113% from FY 2020). Net income: €3.94m (up €4.64m from FY 2020). Profit margin: 17% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth. Announcement • Jan 19
LIMES Schlosskliniken AG Provides Earnings Guidance for 2022 LIMES Schlosskliniken AG provided earnings guidance for 2022. For the period, the company expects sales to be EUR 27.0 million (+60) and operating result (EBIT) of EUR 5.4 million. The company anticipates an operating result (EBIT) of EUR 5.4 million. Reported Earnings • Sep 24
First half 2021 earnings released: EPS €5.29 (vs €2.20 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €8.17m (up 79% from 1H 2020). Net income: €1.55m (up €2.20m from 1H 2020). Profit margin: 19% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Reported Earnings • May 16
Full year 2020 earnings released: €2.37 loss per share (vs €2.81 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €11.2m (up 34% from FY 2019). Net loss: €694.4k (loss narrowed 16% from FY 2019). Is New 90 Day High Low • Feb 10
New 90-day high: €109 The company is up 4.0% from its price of €105 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 13% over the same period. Is New 90 Day High Low • Nov 06
New 90-day high: €104 The company is up 15% from its price of €90.50 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 8.0% over the same period. Is New 90 Day High Low • Oct 16
New 90-day high: €101 The company is up 11% from its price of €91.00 on 17 July 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 12% over the same period. Reported Earnings • Sep 28
First half earnings released Over the last 12 months the company has reported total losses of €955.2k, with losses widening by 16% from the prior year. Total revenue was €9.20m over the last 12 months, up 16% from the prior year. Is New 90 Day High Low • Sep 25
New 90-day low: €88.00 The company is down 4.0% from its price of €92.00 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 9.0% over the same period.